Vol. 51 / RR-2 Recommendations and Reports

TABLE 1. Recommended and minimum ages and intervals between vaccine doses*

Vaccine and dose number	Minimum age for this dose	Minimum interval to next dose
Hepatitis B1 _†	Birth	4 wks
Hepatitis B2	4 weeks	8 wks
Hepatitis B3§	6 mos ₁	_
Diphtheria and tetanus toxoids and acellular pertussis (DTaP)1	6 wks	4 wks
DTaP2	10 wks	4 wks
DTaP3	14 wks	6 mos ₁ **
DTaP4	12 mos	6 mos ₁
DTaP5	4 yrs	_
Haemophilus influenzae, type b (Hib)1† #1	6 wks	4 wks
Hib2	10 wks	4 wks
Hib3§§	14 wks	8 wks
Hib4	12 mos	_
Inactivated poliovirus vaccine (IPV)1	6 wks	4 wks
IPV2	10 wks	4 wks
IPV3	14 wks	4 wks
IPV4	18 wks	_
Pneumococcal conjugate vaccine (PCV)1 _{††}	6 wks	4 wks
PCV2	10 wks	4 wks
PCV3	14 wks	8 wks
PCV4	12 mos	_
Measles, mumps, and rubella (MMR)1	12 mos	4 wks
MMR2	13 mos	
Varicella***	12 mos	4 wks***
Hepatitis A1	2 yrs	6 mos ₁
Hepatitis A2	30 mos	_
Influenza _{†††}	6 mos ₁	4 wks
pneumococcal polysaccharide (PPV)1	2 yrs	5 yrs
PPV2	7 yrs§§§	_

^{*} Combination vaccines are available. Using licensed combination vaccines is preferred over separate injections of their equivalent component vaccines (**Source**: CDC. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 1999;48[No. RR-5]:5). When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components; the minimum interval between doses is equal to the greatest interval of any of the individual antigens.

[†] A combination hepatitis B-Hib vaccine is available (Comvax[®], manufactured by Merck Vaccine Division). This vaccine should not be administered to infants aged <6 weeks because of the Hib component.

[§] Hepatitis B3 should be administered >8 weeks after Hepatitis B2 and 16 weeks after Hepatitis B1, and it should not be administered before age 6 months. ¶ Calendar months.

^{**} The minimum interval between DTaP3 and DTaP4 is recommended to be >6 months. However, DTaP4 does not need to be repeated if administered >4 months after DTaP3.

For Hib and PCV, children receiving the first dose of vaccine at age >7 months require fewer doses to complete the series (see CDC. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae, type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR 1991;40[No. RR-1]:1–7, and CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2000;49[No. RR-9]:1–35).

For a regimen of only polyribosylribitol phosphate-meningococcal outer membrane protein (PRP-OMP, PedvaxHib®, manufactured by Merck), a dose administered at age 6 months is not required.

During a measles outbreak, if cases are occurring among infants aged <12 months, measles vaccination of infants aged >6 months can be

undertaken as an outbreak control measure. However, doses administered at age <12 months should not be counted as part of the series (**Source:** CDC. Measles, mumps, and rubella — vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1998;47[No. RR-8]:1–57).

- * Children aged 12 months-13 years require only one dose of varicella vaccine. Persons aged >13 years should receive two doses separated by >4 weeks
- Two doses of inactivated influenza vaccine, separated by 4 weeks, are recommended for children aged 6 months–9 years who are receiving the vaccine for the first time. Children aged 6 months–9 years who have previously received influenza vaccine and persons aged >9 years require only one dose per influenza season.
- Second doses of PPV are recommended for persons at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody concentration. Revaccination 3 years after the previous dose can be considered for children at highest risk for severe pneumococcal infection who would be aged <10 years at the time of revaccination (see CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1997;46[No. RR-8]:1–24).